A patient in Germany treated with the new multiple sclerosis (MS) drug ocrelizumab (Ocrevus, Roche) has been diagnosed with progressive multifocal leukoencephalopathy (PML), a potentially deadly brain infection, after switching from natalizumab (Tysabri, Biogen) following three years of treatment, according to a Reuters report.

The FDA’s Oncologic Drugs Advisory Committee (ODAC) has recommended approval of a proposed epoetin alfa biosimilar (Pfizer) across all indications. This marks the first time a biosimilar erythropoiesis-stimulating agent has been recommended for approval by an FDA advisory committee.

Death rates from Alzheimer’s disease (AD) increased 55% between 1999 and 2014, according to data from the Centers for Disease Control and Prevention (CDC). The number of AD deaths at home also increased during the same period, from 14% to 25%, suggesting an increase in the number of caregivers who would benefit from support, including education a

In May, House Republicans voted to repeal and replace the Patient Protection and Affordable Care Act (PPACA). Subsequently, Republicans in the Senate began working on their own legislation to do the same. While the fate of the Senate bill is uncertain, three “immutable” trends in the U.S.

Senate Republican staff members will be working on their own legislation to repeal and replace the Patient Protection and Affordable Care Act (PPACA) during the upcoming recess, according to an article posted on the Politico website. The week-long Senate hiatus will begin on Monday, May 29.

We’ve been seeing some mean moves lately. Someone appointed to a high government post by President Trump states a position that is then undermined by the Commander-in-Chief. The appointee has to backtrack—picture Michael Jackson doing his moonwalk.

The human immunodeficiency virus (HIV) vaccine Pennvax-GP has produced among the highest immune response rates (humoral and cellular) ever demonstrated in a human study by an HIV vaccine, according to a report from its developer, Inovio Pharmaceuticals.

After years of anecdotal claims about its benefits, the cannabis derivative cannabidiol (CBD) has been shown to reduce seizure frequency by 39% in patients with Dravet syndrome—a rare, severe form of epilepsy—in the first large-scale, randomized clinical study of the compound.

The FDA’s Oncologic Drugs Advisory Committee (ODAC) has voted 10 to 3 that the overall risk–benefit profile of oral L-glutamine powder (Endari, Emmaus Life Sciences) for the treatment of patients with sickle cell disease (SCD) is favorable. The FDA has set a PDUFA target action date of July 7, 2017. 

Results from a 12-month study mapping bacterial diversity within a hospital—with a focus on the flow of microbes among patients, staff, and surfaces—should help hospitals worldwide better understand how to promote beneficial microbial interactions and reduce potentially harmful contact.

The Congressional Budget Office (CBO) and the staff of the Joint Committee on Taxation (JCT) have completed an estimate of the direct spending and revenue effects of the revised American Health Care Act (AHCA), as passed by the House of Representatives.

About 67,000 people living in 30 counties in northwestern Missouri and another two in Kansas will not have an Obamacare plan available to them next year.

Excellent breakdown in the Wall Street Journal this morning about what we can describe (being only a tad hyperbolic) as the bombshell of a CBO report that landed last night. It says that the American Health Care Act, as passed by the House, would result in 23 million more Americans being uninsured.

In the fight against super bacteria, scientists at the University at Buffalo (UB) are relying on strength in numbers to overcome drug resistance.

The FDA’s Oncologic Drugs Advisory Committee (ODAC) has voted 12 to 4 in favor of approving the experimental breast cancer drug neratinib (Nerlynx, Puma Biotechnology) for use in patients who have already had their tumors surgically removed. The panel observed, however, that the treatment’s clinical benefit was only “modest.”